We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lab-On-Chip Platform to Expedite Cancer Diagnoses

By LabMedica International staff writers
Posted on 30 Jan 2025

Cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in every six deaths worldwide. More...

Timely cancer diagnosis remains a major challenge, as abnormal cellular growth is often detected too late. Early diagnosis is critical, and recent research has focused on detecting rare circulating tumor cells (CTCs) in peripheral blood as noninvasive markers for diagnosis. However, isolating target cells for examination is inherently difficult. Traditional methods typically require complex sample preparation, substantial equipment, and large sample volumes, and even then, it remains challenging to efficiently separate the cells.

Researchers from K. N. Toosi University of Technology (Tehran, Iran) have now introduced a groundbreaking system that uses standing surface acoustic waves to separate CTCs from red blood cells with remarkable precision and efficiency. The system developed by the team integrates advanced computational modeling, experimental analysis, and artificial intelligence (AI) algorithms to analyze complex acoustofluidic phenomena. By combining machine learning algorithms with data-driven modeling, they were able to fine-tune the system for optimal recovery and cell separation rates. The platform, described in the journal Physics of Fluids, achieves 100% recovery under ideal conditions, while significantly reducing energy consumption through precise control of acoustic pressures and flow rates.

While many methods for enriching particles through microfluidics have been developed, those using acoustofluidics stand out due to their biocompatibility, ability to generate high-force magnitudes at MPa pressure ranges, and production of cell-scale wavelengths. The researchers' novel approach incorporates dualized pressure acoustic fields, which enhance the impact on target cells, and positions them strategically at critical points in the microchannel geometry on a lithium niobate substrate. By applying acoustic pressure within the microchannel, the system generates reliable datasets that reveal cell interaction times and trajectory patterns, helping to predict tumor cell migration.

“We have produced an advanced, lab-on-chip platform that enables real-time, energy-efficient, and highly accurate cell separation,” said researcher Afshin Kouhkord. “The technology promises to improve CTC separation efficiency and open new possibilities for earlier and more effective cancer diagnosis. It also paves the way for microengineering and applied AI in personalized medicine and cancer diagnostics.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.